– CANADA, Vancouver – Lobe Sciences Ltd. (OTC: LOBEF / CSE: LOBE), a biopharmaceutical company specializing in developing transformative medicines for rare diseases, has appointed Dr. Frederick Sancilio (Ph.D.) to its Board of Directors, effective immediately.
About Dr. Frederick Sancilio
Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research to Lobe Sciences. He completed his B.S., M.S., and Ph.D. in Physical and Analytical Chemistry at Rutgers, The State University of New Jersey. Notably, he founded aaiPharma, Inc., which became a leading dosage form development company with numerous US FDA and European drug approvals. Dr. Sancilio has also founded and led multiple successful pharmaceutical ventures, significantly contributing to the industry in North Carolina.
Dr. Frederick Sancilio said, “I am excited to contribute to Lobe’s innovative approach to mental health treatment. The company’s dedication to exploring non-psychedelic treatments for unmet medical needs aligns closely with my passion for pioneering new therapies.”
Beyond his pharmaceutical career, Dr. Sancilio established Sancilio & Company, Inc., a specialty pharmaceutical company in Palm Beach County, Florida, focused on diseases with unmet medical needs. He also co-founded Clearway Global, Inc., a consulting and product development firm, and serves as a Research Professor at Florida Atlantic University.
About Lobe Sciences Ltd.
Lobe Sciences is focused on developing transformative medicines for rare diseases, leveraging collaborations with industry leaders to conduct research and development using non-hallucinatory doses of stabilized psilocin compounds for orphan neurological therapeutic applications.
For more information: https://lobesciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.